

1 **Category :** Original Article

2 **Title:** Viral Dynamics Matter in COVID-19 Pneumonia: the success of early treatment with
3 hydroxychloroquine and azithromycin in Lebanon.

4

5 **Authors:**

6 Amanda Chamieh^{1,2}, Claude Afif², Gerard El-Hajj³, Omar Zmerli², Isabelle Djaffar-
7 Jureidini⁴, Roy A. Raad³, Raja Ashou³, Georges Juvelekian⁵, Jean-Marc Rolain¹ and Eid
8 Azar^{2*}

9

10 **Affiliations:**

11 1- Aix-Marseille Université, AP-HM, Institut de Recherche pour le Développement
12 (IRD), Microbes Evolution Phylogeny and Infections (MEPHI), Institut Hospitalo-
13 Universitaire Méditerranée-Infection, Marseille, France.

14 2- Division of Infectious Diseases, Saint George Hospital University Medical Center,
15 Beirut, Lebanon.

16 3- Department of Radiology, Saint George Hospital University Medical Center, Beirut,
17 Lebanon.

18 4- Department of Laboratory Medicine, Saint George Hospital University Medical
19 Center, Beirut, Lebanon.

20 5- Department of Pulmonary and Critical Care Medicine, Saint George Hospital
21 University Medical Center, Beirut, Lebanon.

22

23 **Running Title:** Viral Dynamics Matter in COVID-19 Pneumonia

24

25 **Declarations of Interest and Funding/Support Statement:**

26 This research did not receive any specific grant from funding agencies in the public,
27 commercial, or not-for-profit sectors.

28 **Acknowledgements:**

29 This work was supported by the Saint George Hospital University Medical Center
30 Beirut, Lebanon.

31 ***Corresponding Author:**

32 Eid Azar, M.D.

33 Infectious Disease, Chief of Staff

34 Associate Chief Medical Officer for Safety, Risk Management, and Infection Prevention and

35 Control

36 Saint George Hospital University Medical Center, Youssef Sursock St. – Achrafieh, Beirut,

37 Lebanon; eeazar@stgeorgehospital.org; +961 03 665358

38

39

40

41 **Category:** Original Article

42

43 **Title:** Viral Dynamics Matter in COVID-19 Pneumonia: the success of early treatment with
44 hydroxychloroquine and azithromycin in Lebanon.

45

46 **Running Title:** Viral Dynamics Matter in COVID-19 Pneumonia

47 1. Abstract

48 1.1. Background/Purpose

49 We share our experience in COVID-19 pneumonia management at Saint George Hospital
50 University Medical Center (SGHUMC) in Lebanon. In the absence of a standard of care,
51 early diagnosis and opt-in therapy with Hydroxychloroquine and Azithromycin were offered.

52 1.2. Methods

53 We reviewed records of COVID-19 pneumonia patients from March 16-April 26 2020. Based
54 on NEWS score, we stratified patients as A: low B: medium, and C: high clinical severity and
55 obtained pharmacotherapy data. Chest-CT-severity-score (CTSS) was used. We defined
56 clinical cure as resolution of symptoms and biomarkers and virologic cure as a PCR above 35
57 cycles(Ct).

58 1.3. Results

59 We recorded 21 COVID-19 pneumonia patients of whom 19 opted for treatment. Clinical
60 symptoms and laboratory markers at presentation did not significantly correlate with severity.
61 Lower initial viral load significantly correlated with lower levels of clinical and radiological
62 severity ($p=0.038$). Virologic cure, $Ct > 35$, by day 10, was only 33% in high severity
63 significantly less than categories A and B. We observed 100% clinical cure at day 10 in
64 Category-A, 67% in B, and 33% in C ($p < 0.05$). Patients with the lowest severity had the
65 fastest virologic cure in a mean of 5.8 days from diagnosis, shortest hospitalization and
66 earlier radiological improvement ($p < 0.005$). Ultimately, 18 patients were discharged home in
67 good condition and one remains in the ICU.

68 1.4. Conclusion:

69 Viral dynamics matter in COVID-19 pneumonia. An early control of replication may be
70 crucial in averting complications. Early administration of Hydroxychloroquine and

71 Azithromycin potentially explains our 94.7% success rate in treating a fairly complex cohort
72 of COVID-19 pneumonia.

73

74 Keywords:

75 COVID-19 pneumonia

76 Viral Load Dynamics in SARS-CoV-2

77 Hydroxychloroquine and Azithromycin in COVID-19

78

79 2. Introduction

80 SARS-CoV-2 is a novel coronavirus that is taking the world as we know it by storm.

81 In Lebanon, on February 21 2020, SARS-CoV-2 was first diagnosed in a female
82 returning from the epicenter in Iran. Subsequently, the Lebanese government closed early
83 on schools and enterprises, banned gatherings, and advised social distancing and home
84 quarantine. Until April 26 2020, Lebanon is at 704 cases in a country of an estimated 6.7
85 million inhabitants.¹

86 Globally, the approaches to managing COVID-19 pandemic are diverse. One method
87 advocates conservative, home-stay for mild cases while reserving diagnostics and medical
88 intervention for severe cases. Another main strategy is almost opposite and relies on early
89 diagnosis by offering RT-PCR testing^{2,3}.

90 At Saint George Hospital University Medical Center (SGHUMC) in Lebanon, we
91 formed the SGHUMC COVID-19 response team and carefully reviewed existing
92 evidence and management strategies. We opted for an early detection approach.

93 We tested all incoming patients with an acute respiratory, febrile illness or known
94 exposure for SARS-CoV-2 by RT-PCR, traced their contacts, and performed prompt
95 chest CT scan imaging as indicated.

96 In the absence of a standard of treatment for COVID-19, we assessed available
97 therapies. Hydroxychloroquine and azithromycin are readily available promising
98 combination with a familiar pharmacologic profile. On the other hand, lopinavir/ritonavir
99 lacks significant clinical benefits and remdesivir use is restricted to clinical trials or
100 compassionate use. These two options above are not available in Lebanon. IL-6 pathway
101 inhibitors and convalescent plasma treatment are in trial reserved for advanced COVID-
102 19. Therefore, we agreed to consider them on a case-by-case basis.⁴⁻⁹

103 In summary, patients with COVID-19 pneumonia chose either no pharmacological
104 treatment or the combination of Hydroxychloroquine and azithromycin. Patients opting
105 for the Hydroxychloroquine and azithromycin regimen consented verbally after having
106 the risks and potential benefits of this regimen well explained to them.

107 In this retrospective study, we share our experience with COVID-19 pneumonia
108 clinical and radiological presentations and outcomes, course of illness, and viral
109 dynamics.

110 3. Methods

111 3.1. Study setting and Design

112 We conducted this retrospective study at SGHUMC in Beirut, Lebanon, from
113 March 16, 2020 until April 26, 2020.

114 Patients were received via our Emergency Room and Corona Clinic or as
115 transfers requiring urgent critical care, some of which were COVID-19 confirmed.

116 We obtained exposure and contact history of all incoming patients with
117 respiratory or febrile illnesses and performed a physical exam. Nasopharyngeal and
118 oropharyngeal swabs were obtained for SARS-CoV-2 RT-qPCR. Chest CT imaging was
119 done within 3 days of diagnosis.

120 The SGHUMC response team was composed of infectious disease physicians,
121 pulmonary and critical care physicians, radiologists, infection preventionists, nursing
122 department, laboratory department, and a representative from hospital leadership.

123 Clinical and virologic cure was assessed at day 10 from diagnosis. Patients were
124 followed until complete clinical and virologic clearance, defined as the overall outcome.

125 3.2. Inclusion Criteria

126 In our analysis, we included all patients that were positive for SARS-CoV-2
127 by RT-qPCR with findings of pneumonia on chest CT scan and had received
128 Hydroxychloroquine and azithromycin for at least 72 hours.

129 3.3. Data Collection

130 We retrieved data from the electronic database of the COVID-19 clinic and
131 emergency care service. We recorded patient age, gender, history of cardiovascular
132 disease, hypertension, chronic lung conditions, diabetes mellitus, malignancy, and any
133 immunosuppressive therapy. We also recorded possible exposure history and

134 reported symptoms of cough, fever, headache, shortness of breath, chills, myalgias,
135 sore throat, rhinorrhea, and diarrhea.

136 The time from symptom onset to diagnosis, imaging and treatment initiation,
137 length of hospital stays, the need for oxygenation, and whether the patient was
138 transferred to the intensive care unit (ICU) were retrieved. Laboratory markers
139 included CBC, Creatinine, CRP, Troponin, Procalcitonin, Urea, Na, K, Ca, Mg, AST,
140 ALT, Bilirubin, LDH, D-Dimer, Ferritin, and Fibrinogen depending on the case.

141 We considered day zero as the day of diagnosis of COVID-19 by RT-qPCR.
142 At day 10, patients were assessed for clinical and virologic cure. Some patients
143 underwent a repeat chest CT scan.

144 3.4. Clinical Assessment:

145 We used the National Early Warning Score (NEWS) and chest CT scan findings to
146 assess acute clinical severity on admission.¹⁰ The NEWS is based on physiologic
147 parameters that include respiratory and heart rate, blood pressure, oxygen saturation, use
148 of supplemental oxygen, and state of consciousness. A NEWS score of 0-4, 5-6, and 7-15
149 respectively corresponded to low, medium, and high scores. For the sake of data analysis,
150 we then divided our cohort into categories A, B, and C according to low, medium, and
151 high NEWS score.

152 We define clinical cure as the resolution of symptoms, clinical stabilization, and
153 normalization of inflammatory markers.

154 Patients were managed as inpatients or followed as outpatients depending on
155 their clinical severity. Outpatients were discharged with strict instructions and
156 education, and were called for follow up every 2 days.

157 3.5. PCR Assay

158 RNA was extracted from nasopharyngeal/oropharyngeal samples. Real-time
159 reverse transcriptase PCR (RT-qPCR) detection of SARS-CoV-2 was done using the
160 LightMix® Modular SARS-CoV-2 (COVID19) E, N, and RdRP-genes (Tib
161 Molbiol, Berlin, Germany) as previously described.^{11,12} We used the cycle number
162 threshold values (Ct) as an indicator of the number of copies of SARS-CoV-2 present
163 in our samples. We define virologic cure as 2 consecutive SARS-CoV-2 RT-qPCR
164 with Ct>35, as previously described.¹³

165 We considered a patient with virologic cure by day 10 of diagnosis a fast
166 responder and a slow responder if more than 10 days. All patients were followed with
167 serial RT-PCR till negative, beyond limit of detection of the test, as part of SGHUMC
168 infection control strategy.

169 We also tested for other pathogens using Biofire® FilmArray® Respiratory 2
170 Panel (BioMerieux, France) following manufacturer's instructions.

171 3.6. Radiologic Assessment:

172 Non-enhanced low-dose chest CT scans were obtained in supine position on a
173 "GE Healthcare: Discovery CT750 HD" CT scanner, dedicated for confirmed or
174 suspected COVID-19 patients. Patients were instructed to hold their breath, and
175 acquisition was made at end-inspiration.

176 COVID-19 typical findings were recorded, including: (a) ground-glass
177 opacities, (b) dense airspace consolidation, (c) interlobular septal thickening, (d)
178 vascular enlargement, (e) peripheral, subpleural distribution, and (f)
179 multifocal/multilobar/bilateral involvement. The presence of pleural effusion and
180 other findings atypical for pneumonia was also assessed. Chest CT severity score
181 (CTSS) was determined to estimate the severity of lung involvement in patients with
182 COVID-19 pneumonia. The scoring system was adapted from similar scoring systems

183 used in recent COVID-19 literature.^{14,15} A score of 0, 1, 2, or 3 (corresponding to
184 involvement of 0%, 0-25%, 25-50%, and >50% respectively) was assigned for each
185 lobe of the 5 lung lobes with a maximum total score of 15. Therefore, if a patient has
186 a CTSS of 15, it indicates that there is more than 50% involvement of the lung.
187 Interval improvement and resolution is a decrease in CTSS and/or subjective decrease
188 in ground-glass opacities density.

189 All images were anonymized then analyzed by two experienced radiologists
190 (R.A. and R.R.) independently. In case of discrepant CT findings or CTSS, a final
191 decision was reached by consensus.

192 3.7. Treatment:

193 3.7.1. Pharmacologic therapy for patients receiving Hydroxychloroquine and 194 azithromycin

195 We verified for any drug-drug interactions, G6PD deficiency and
196 contraindications, and we obtained an ECG. If $QTc < 460$ msec, treatment was initiated.
197 ¹⁶ When $QTc > 460$ msec, we consulted a cardiologist that ordered continuous cardiac
198 monitoring by telemetry if needed. ECG was repeated on day 2 and day 10 upon
199 completion of therapy.

200 We administered 600mg of Hydroxychloroquine per os per day for 10 days
201 and a 500mg loading dose of azithromycin followed by 250mg/day for 4 days
202 intravenously or orally.

203 3.7.2. Non-pharmacologic Treatment:

204 Supportive and symptomatic therapy, such as oxygen, was assessed individually.

205 3.8. Statistics

206 The Shapiro-Wilk test was used to assess normality. Data were expressed
207 as mean \pm SD and/or median [minimum; maximum]. The nonparametric Man-

208 Whitney U or Kruskal-Wallis H test was applied to assess for differences between
209 categories. The Wilcoxon signed-rank test was used to assess improvement in
210 CTSS values on follow-up CT. A Spearman's rank-order correlation was used for
211 interrater reliability between the radiologists' CTSS. The rank-based Jonckheere-
212 Terpstra test was applied to trend the 3 clinical severity groups and cycle threshold
213 numbers. P-values<0.050 were significant.

214 3.9. Ethical Statement:

215 We obtained SGHUMC IRB approval for a retrospective review of the charts of
216 COVID-19 patients. It is standard procedure that all patients sign a general informed
217 consent for receiving medical acts and care.

218 4. Results

219 Out of 860 patients that presented to our COVID-19 clinic, 27 patients had SARS-
220 CoV-2 RT-PCR positive nasopharyngeal swabs at our institution. Six of the 27 patients
221 were asymptomatic with a normal chest CT scan. Two of the remaining 21 patients with
222 COVID-19 typical pneumonia features on chest CT scan refused pharmacologic
223 treatment and followed-up with their physicians. These 8 patients were excluded.

224 Finally, 19 patients were included, all opting for treatment with the combination of
225 Hydroxychloroquine and azithromycin.

226 To note, two patients, not diagnosed nor initially treated at SGHUMC, were
227 transferred to SGHUMC for critical care. Both had advanced COVID-19 and died within
228 72 hours of admission. These two patients were excluded.

229 The mean age in our study cohort was 57.8 ± 16.4 years. Category A of low clinical
230 severity was composed of 4 males and 6 females, with a median age of 51[28;85].
231 Category B was composed of 5 males and 1 female, median age 59[52;67]. Category C
232 was composed of 2 males and 1 female, median 81[55;87]. No statistical difference
233 observed in ages across the 3 categories. We observed a higher ratio of 11 males to 8
234 females.

235 As for comorbidities, 4 patients in category A had hypertension (HTN) and another 4
236 had dyslipidemia. In category B, one patient was a smoker with mild chronic bronchitis,
237 and another one had coronary artery disease (CAD), HTN, and dyslipidemia. In category
238 C, one patient had CAD, HTN and dyslipidemia while another was a smoker. None of the
239 patients were known diabetics.

240 Only 1 patient with COVID-19 pneumonia of medium NEWS score was co-infected
241 with RSV.

242 4.1. Clinical Course and Cure

243 The median duration from initial symptom onset to diagnosis of COVID-19
244 was 3.5[1;18] days in category A, 8[2;12] days in category B and 4[2;8] days in
245 category C. This was not statistically significant.

246 At initial evaluation, there was no significant variation between symptoms
247 reported by patients. They reported fever in 15/19, cough in 13/19, shortness of
248 breath in 9/19, myalgias in 5/19, sore throat in 4/19, chills in 2/19, headache in 2/19,
249 and 1/19 with fatigue. Anosmia was reported by 1 patient.

250 We also found no significant difference in laboratory markers among patients
251 of all categories upon presentation.

252 4.1.1. Clinical Course

253 The length of stay of patients in category A was a mean of 3 ± 4.8 days, median
254 1[0;12] days, significantly lower than both category B at a mean of 11 ± 4.8 days; median
255 12.5[3,16] days ($p=0.032$) and category C at a mean of 20 ± 8.5 days, median of 19[12,29]
256 days($p=0.015$). No statistical significance in LOS between medium and high clinical
257 severity.

258 There was no distinct pattern for progression of laboratory markers. However, when
259 peak values are reached, it took 4-6 days to return to baseline. This was independent of
260 initial clinical severity. Table 1 represents the results of available blood tests during the
261 study period per category. On average, category A of low clinical severity had an overall
262 significantly lower CRP, Procalcitonin, LDH, Ferritin, D-Dimer, and lymphopenia.

263 4.1.2. Clinical Cure at day 10:

264 All patients in category A achieved clinical cure on day 10 compared to 4/6 in
265 category B. In category C, only 1 patient achieved clinical cure at day 10. Thus,
266 100% clinical cure at day 10 in low clinical severity, 67% in medium severity, and
267 33% in high severity COVID-19. This trend was statistically significant ($p=0.031$).

268 4.1.3. Overall Clinical Outcome

269 Eighteen out of 19 patients were discharged home in good condition, a clinical
270 success rate of 94.7%. Only 1 patient in category C was still on mechanical
271 ventilation. This patient is the eldest in the cohort at 87 years and had the highest
272 NEWS score of 9 on admission.

273 None of the patients developed any drug related adverse events.

274 4.2. Virologic Load Dynamics

275 4.2.1. Initial Viral Load:

276 A higher initial SARS-CoV-2 RT-PCR Ct reflects a lower viral load. There was a
277 statistically significant trend of higher Ct value with lower levels of clinical severity
278 ($p=0.038$). Median Ct in category A was 33.5(13,38) which is significantly lower than
279 that of category B at Ct= 30[23,35]. This was also significantly lower than the initial
280 Ct in category C of 24[13,29] (Figure 1A).

281 4.2.2. Virologic Outcome at Day 10

282 In category A, PCR results were available for only 8/10 patients, and 6/8 patients
283 achieved virologic cure at day 10 in a mean of 5.8 ± 4.2 days. In category B, PCR
284 results were available for 5/6 patients, and 4 achieved virologic cure in a mean of
285 9.2 ± 4.2 days. In category C, only 1/3 patients achieved virologic cure in 4 days.
286 (Figure 2)

287 4.2.3. Overall Virologic Cure

288 At the end of the study, SARS-CoV-2 RT-PCR results were available for all
289 patients. In category A, eight of ten patients achieved virologic cure, beyond the limit
290 of detection of our test at mean of 14.8 ± 7.7 days. In category B, all patients achieved
291 virologic cure beyond limit of detection of our test and clinical cure at a mean of

292 16±5 days. As for category C, only 2 out of the 3 patients achieved virologic cure
293 beyond limit of detection of our test on days 21 and 24. (Figure 2)

294 Patients with lower clinical severity reached virologic cure significantly faster
295 than those of higher severity (p=0.042).

296 4.3. Radiologic Findings:

297 There was a strong, positive correlation between the two readers R.A. and
298 R.R., which was statistically significant (rs(36) = 0.958, p < 0.001).

299 All patients had a chest CT scan done within 3 days of COVID-19 diagnosis.
300 To note, the median time from symptom onset to imaging was 3 days for categories A
301 and C and 8 days for category B. (p = 0.842).

302 On initial CT, there was a statistically significant difference in chest CT
303 Severity Score(CTSS) between the 3 categories (p = 0.012) (Figure 1B). Patients of
304 category B showed the highest median CTSS of 10/15 compared to A and C (4/15 (p
305 = 0.003) and 6/15 (p = 0.192), respectively). (Figures 3,4).

306 Only 15 patients underwent follow-up chest CT scans at a median of 14 days
307 (range 10-26 days). Thirteen (87%) patients showed significant interval improvement
308 of which two patients showed complete resolution (p = 0.031). (Figure 5)

309 The remaining two patients with worsening features on second CT showed
310 significant improvement on the subsequent third CT scan (Figure 6), obtained on day
311 20 and 29 respectively.

312 The median follow-up interval from time of diagnosis to radiological
313 improvement for the 15 patients was: 14 (10-24), 12 (10-29), and 20 (14-26) days for
314 categories A, B, and C respectively.

315

316 5. Discussion

317 At SGHUMC, 78% of patients diagnosed with COVID-19 had pneumonia on chest CT
318 scan. Symptoms such as shortness of breath and dyspnea were not reliably predictive of
319 disease severity. Our low threshold to perform chest CT scan was crucial in early diagnosis.

320 In our cohort, an initially low viral load was associated with less severe clinical and
321 radiological findings, and faster viral clearance. All patients in category A achieved clinical
322 cure in 10 days and had the fastest virologic cure in a mean 5.8 days from diagnosis. In
323 contrast, only 56% of patients of higher clinical severity achieved clinical cure in 10 days,
324 had longer hospital stays, and a more prolonged viral shedding. A recent study on 1061
325 patients with COVID-19 at IHU-Mediterranee Infection in Marseille, France showed that
326 patients with higher initial viral load were less likely to have a low clinical severity and more
327 likely to have poor virologic outcome.¹⁷ Our results are consistent with their findings
328 confirming that initial viral load and kinetics of viral clearance matter in COVID-19.

329 In many viral infections, early control of viral replication is crucial for better outcomes.
330 Hydroxychloroquine has an antiviral effect that is proven in-vitro and in-vivo.¹⁸⁻²³ We had a
331 94.7% success rate in treating a fairly complex cohort of COVID-19 pneumonia, with 18/19
332 patients discharged at baseline conditions. None of our 19 pneumonia patients had a cytokine
333 storm, and all had a rapid decline within 4 days from peak inflammatory laboratory markers.
334 The latter is likely a result of virologic control and possible early attenuation of cytokine
335 storm.^{7,24,25}

336 Chest CT scan is a helpful diagnostic tool but also serves to monitor progression. Thirteen
337 of 15 follow-up chest CT scans improved within 14 days. The remaining two showed
338 improvement in a third scan beyond 20 days. In fact, all patients improved, showing either
339 complete resolution or marked improvement in the CT findings, mainly ground-glass
340 opacities and parenchymal consolidations. A follow-up chest CT may be necessary in

341 patients with COVID-19 to monitor for secondary organizing pneumonia and subsequent
342 fibrosis, similar to outcomes seen with SARS and MERS.¹⁴ We will continue to monitor our
343 patients for such complications despite the current significant radiologic improvement.

344 Our observational retrospective cohort is not designed to measure the direct impact of
345 hydroxychloroquine and azithromycin treatment on the outcome of COVID-19 pneumonia.
346 However, in 10 days, 80% of patients with varying severity of pneumonia reached clinical
347 cure, and 70% achieved a virologic cure. Hence, early diagnosis of COVID-19 pneumonia
348 coupled with administering Hydroxychloroquine and azithromycin treatment contributed to
349 faster clinical and radiologic resolution and virologic clearance, potentially averting
350 complications.

351 In conclusion, it is clear that higher viral load and prolonged viral shedding results in a
352 longer and more complex clinical course. Our experience in early patient tracing, testing,
353 chest imaging, and treatment of COVID-19 of mild, moderate, and severe pneumonia with
354 Hydroxychloroquine and azithromycin resulted in a 95% success rate with no mortality.
355 Further studies outside of a pandemic setting are needed to fully and fairly demonstrate the
356 impact of early treatment of COVID-19 pneumonia with Hydroxychloroquine and
357 azithromycin on overall patient outcome, long-term lung damage and reduction of the
358 transmission of SARS-CoV-2.

359 6. References

- 360 1. Coronavirus disease 2019 [Internet]. [cited 2020 Apr 21]. Available from:
361 <https://www.who.int/emergencies/diseases/novel-coronavirus-2019>
- 362 2. Amrane S, Tissot-Dupont H, Doudier B, Eldin C, Hocquart M, Mailhe M, et al. Rapid
363 viral diagnosis and ambulatory management of suspected COVID-19 cases presenting
364 at the infectious diseases referral hospital in Marseille, France, - January 31st to March
365 1st, 2020: A respiratory virus snapshot. *Travel Med Infect Dis.* 2020 Mar;101632.
- 366 3. Bai Y, Yao L, Wei T, Tian F, Jin DY, Chen L, et al. Presumed Asymptomatic Carrier
367 Transmission of COVID-19. Vol. 323, *JAMA - Journal of the American Medical*
368 *Association.* American Medical Association; 2020. p. 1406–7.
- 369 4. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for
370 Coronavirus Disease 2019 (COVID-19): A Review. *Jama* [Internet]. 2020;2019.
371 Available from: <http://www.ncbi.nlm.nih.gov/pubmed/32282022>
- 372 5. Zhai P, Ding Y, Wu X, Long J, Zhong Y, Li Y. The epidemiology, diagnosis and
373 treatment of COVID-19. *Int J Antimicrob Agents* [Internet]. 2020;(xxxx):105955.
374 Available from: <https://doi.org/10.1016/j.ijantimicag.2020.105955>
- 375 6. Colson P, Rolain J-M, Lagier J-C, Brouqui P, Raoult D. Chloroquine and
376 hydroxychloroquine as available weapons to fight COVID-19. *Int J Antimicrob Agents*
377 [Internet]. 2020;105932. Available from:
378 <http://www.ncbi.nlm.nih.gov/pubmed/32145363>
- 379 7. Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et al.
380 Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an
381 open-label non-randomized clinical trial. *Int J Antimicrob Agents.* 2020;
- 382 8. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A Trial of Lopinavir–Ritonavir
383 in Adults Hospitalized with Severe Covid-19. *N Engl J Med* [Internet]. 2020 Mar 18

- 384 [cited 2020 Apr 29];NEJMoa2001282. Available from:
385 <http://www.nejm.org/doi/10.1056/NEJMoa2001282>
- 386 9. Wang L, Wang Y, Ye D, Liu Q. A review of the 2019 Novel Coronavirus (COVID-19)
387 based on current evidence. *Int J Antimicrob Agents* [Internet]. 2020;105948. Available
388 from: <https://doi.org/10.1016/j.ijantimicag.2020.105948>
- 389 10. Royal College of Physicians. National Early Warning Score (NEWS) 2. Standardising
390 the assessment of acute-illness severity in the NHS Updated report of a working party
391 Executive summary and recommendations. 2017;(December):1–15. Available from:
392 www.rcplondon.ac.uk
- 393 11. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection
394 of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Euro Surveill.*
395 2020;25(3).
- 396 12. Pfefferle S, Reucher S, Nörz D, Lütgehetmann M. Evaluation of a quantitative RT-
397 PCR assay for the detection of the emerging coronavirus SARS-CoV-2 using a high
398 throughput system. *Euro Surveill.* 2020;25(9):1–5.
- 399 13. La Scola B, Le Bideau M, Andreani J, Hoang VT, Grimaldier C, Colson P, et al. Viral
400 RNA load as determined by cell culture as a management tool for discharge of SARS-
401 CoV-2 patients from infectious disease wards. *Eur J Clin Microbiol Infect Dis* Off
402 *Publ Eur Soc Clin Microbiol.* 2020;20–2.
- 403 14. Wang Y, Dong C, Hu Y, Li C, Ren Q, Zhang X, et al. Temporal Changes of CT
404 Findings in 90 Patients with COVID-19 Pneumonia: A Longitudinal Study. *Radiology*
405 [Internet]. 2020 Mar 19 [cited 2020 May 9];200843. Available from:
406 <http://pubs.rsna.org/doi/10.1148/radiol.2020200843>
- 407 15. Pan F, Ye T, Sun P, Gui S, Liang B, Li L, et al. Time Course of Lung Changes On
408 Chest CT During Recovery From 2019 Novel Coronavirus (COVID-19) Pneumonia.

- 409 Radiology. 2020 Feb 13;200370.
- 410 16. Hache G, Marc Rolain J, Gautret P, Deharo J-C, Brouqui P, Raoult D, et al.
411 Combination of hydroxychloroquine plus azithromycin as potential treatment for
412 COVID 19 patients: pharmacology, safety profile, drug interactions and management
413 of toxicity.
- 414 17. Million M, Lagier J, Gautret P, Colson P, Fournier E, Amrane S, et al. Early treatment
415 of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective
416 analysis of 1061 cases in Marseille, France. *Travel Med Infect Dis* [Internet].
417 2020;101738. Available from: <https://doi.org/10.1016/j.tmaid.2020.101738>
- 418 18. Rolain JM, Colson P, Raoult D. Recycling of chloroquine and its hydroxyl analogue to
419 face bacterial, fungal and viral infections in the 21st century. *Int J Antimicrob Agents*.
420 2007;30(4):297–308.
- 421 19. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In Vitro Antiviral Activity and
422 Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of
423 Severe Acute Respiratory Syndrome Main point□: Hydroxychloroquine was found to
424 be more potent than chloroquine at inhibiting SARS-CoV-2 in vit. *Clin Infect Dis*.
425 2020;2:1–25.
- 426 20. Weston S, Haupt R, Logue J, Matthews K, Frieman MB. FDA approved drugs with
427 broad anti-coronaviral activity inhibit SARS-CoV-2 in vitro. 2020;(3).
- 428 21. Devaux CA, Rolain J-M, Colson P, Raoult D. New insights on the antiviral effects of
429 chloroquine against coronavirus: what to expect for COVID-19? *Int J Antimicrob*
430 *Agents* [Internet]. 2020;(December 2019):105938. Available from:
431 <https://doi.org/10.1016/j.ijantimicag.2020.105938>
- 432 22. Viveiros Rosa SG, Santos WC. Clinical trials on drug repositioning for COVID-19
433 treatment. 2020;1–7. Available from: <https://doi.org/10.26633/RPSP.2020.40>

- 434 23. Andreani J, Le Bideau M, Dufлот I, Jardot P, Rolland C, Boxberger M, et al. In vitro
435 testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows
436 synergistic effect. *Microb Pathog.* 2020 Aug 1;145:104228.
- 437 24. Ashraf MA, Shokouhi N, Shirali E, Davari-tanha F, Memar O, Kamalipour A, et al.
438 COVID-19 in Iran, a comprehensive investigation from exposure to treatment
439 outcomes. *medRxiv [Internet]*. 2020 [cited 2020 May 9];2020.04.20.20072421.
440 Available from:
441 <http://medrxiv.org/content/early/2020/04/24/2020.04.20.20072421.abstract>
- 442 25. Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, et al. Hydroxychloroquine in
443 patients with COVID-19: an open-label, randomized, controlled trial. *medRxiv.*
444 2020;2020.04.10.20060558.
- 445
- 446

447 7. Table/Figure Legends

448 7.1. Table 1: *Laboratory Markers of Patients in Category A, B, and C of low, medium*
449 *and high clinical severity*

450 7.2. Figure 1: (A) Initial viral load: A higher initial SARS-CoV-2 RT-PCR cycle
451 threshold number (Ct) reflects a lower viral load. There was a statistically significant
452 trend of higher Ct value with lower levels of clinical severity ($p=0.038$). (B) Initial
453 Chest CT Severity Score (CTSS): On initial CT, there was a statistically significant
454 difference in CTSS between the 3 categories ($p = 0.012$). Patients of category B of
455 medium clinical severity had higher CTSS than category A (low clinical severity) (p
456 $= 0.003$) and category C (high clinical severity) ($p = 0.192$).

457 7.3. Figure 2: Viral Dynamics from day of diagnosis till negativity. *x-axis*: Days since
458 diagnosis of COVID-19 pneumonia. *y-axis*: SARS-CoV-2 RT-PCR cycle threshold
459 number (Ct) follow up according to low(A), medium(B), and high(C) clinical
460 severity. Patients with lower clinical severity reached virologic cure significantly
461 faster than those of higher severity ($p=0.042$).

462 7.4. Figure 3: Axial serial chest CT images of a 66-year-old female with cough, fever,
463 and shortness of breath (category A). Baseline chest CT demonstrating multilobar
464 ground-glass opacities and dense consolidations predominantly in a peripheral
465 subpleural distribution, with associated interlobular septal thickening (“crazy paving
466 pattern”) and vascular enlargement sign (arrows). Chest CT Severity Score was
467 estimated at 9/15. Clinically cured at day 10, and virologic cure confirmed after 21
468 days.

469 7.5. Figure 4: Axial serial chest CT images of a 59-year-old female (category B) with
470 cough, fever, shortness of breath. Baseline chest CT demonstrating multilobar
471 ground-glass opacities and dense consolidations predominantly in a peripheral

472 subpleural distribution, with associated mild septal thickening. Chest CT Severity
473 Score was estimated at 12/15.

474 7.6. Figure 5: Three patients with COVID-19 pneumonia findings including peripheral
475 subpleural ground glass opacities and dense consolidations in the lower lobes (A and
476 C) and in the right lower lobe (B), with near-complete resolution on follow-up CTs
477 (D,F and G). Chest CT Severity Score also improved on follow-up exams.

478 7.7. Figure 6: Chest CT of a 29-year-old female with fever, myalgia, and possible contact
479 with COVID-19 positive case. Baseline chest CT (Day 1) showing a solitary rounded
480 mixed attenuation opacity in the right lower lobe. Findings worsened on the initial
481 follow-up chest CT (Day 12), with multiple new ground-glass opacities in the right
482 lower lobe (B), then completely resolved on the subsequent follow-up CT (Day 29).











